content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Applied Genetic Technologies Corporation (AGTC)

4.70
0.05
(1.08%)
Sep 11, 4:00PM EDT
content_middle

Applied Genetic Technologies Corporation (AGTC), a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases in the United States. The company’s lead product candidates in the preclinical stage comprise treatments for X-linked retinoschisis, Congenital Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. It also has completed preclinical proof-of-concept studies, and Phase I and Phase II clinical trials of a treatment for alpha-1 antitrypsin deficiency, an inherited orphan lung disease. In addition, the company has proof-of-concept programs for other eye diseases, such as leber congenital amaurosis (type 2), and wet form of age-related macular degeneration. It has strategic collaboration agreements with SAFC Pharma; and 4D Molecular Therapeutics. The company was founded in 1999 and is headquartered in Alachua, Florida.

Previous Close: 
4.65
Open: 
4.70
Bid: 
4.50
Ask: 
4.80
1yr Target Price: 
12.75
Day's Range: 
4.60 - 4.80
52wk Range: 
4.45 - 13.33
Volume: 
162436
Average Daily Volume: 
188830
Market Capitalization: 
84.96M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
18076000M
content_right